Jazz Pharmaceuticals EVP Robert Iannone Exercises Options, Sells Shares

What Happened

• Robert Iannone, EVP, Global Head of R&D & CMO at Jazz Pharmaceuticals (JAZZ), exercised stock options on Aug 27, 2026 and sold ordinary shares the same day. He exercised a total of 57,500 shares (27,000 at $113.10 and 30,500 at $137.12) for a total exercise cost of about $7.24M.
• The filing shows open-market sales of 76,921 shares executed at weighted-average prices across multiple trades, generating approximately $19.21M in proceeds. This combination (option exercise followed by share sales) is commonly used to cover exercise costs and/or taxes and is a routine insider liquidity event rather than an explicit bullish or bearish signal.

Key Details

• Transaction date: August 27, 2026; Form 4 filed August 31, 2026 (reporting period Aug 27).
• Option exercises: 57,500 shares acquired (27,000 @ $113.10; 30,500 @ $137.12) — total exercise payments ≈ $7,235,860. (Transaction code M = exercise/conversion.)
• Open-market sales: 76,921 shares disposed in multiple transactions; weighted average sale prices reported per block produced total proceeds ≈ $19,207,097. (Transaction code S = sale.) Footnotes F2–F6 explain the sales were executed in multiple trades and list the price ranges used to compute the reported weighted averages.
• Footnote F1: Sales were made pursuant to a Rule 10b5-1 trading plan adopted May 28, 2026 — transactions occurred automatically under that plan.
• Option provenance: Footnotes F7 and F8 indicate the options were granted under Jazz’s 2011 Equity Incentive Plan with multi-year vesting (grants from 2019 and 2020).
• Shares owned after transaction: not specified in the excerpt provided; see the full Form 4 for post-transaction holdings.
• Filing timeliness: the filing date is Aug 31 for trades on Aug 27; the document does not indicate a late filing status in the provided excerpt.

Context

• These filings reflect option exercises followed by open-market sales. When exercised shares are sold immediately or shortly after (as here), it often indicates a cashless or partially cashless exercise to cover costs/taxes rather than a directional bet on the stock.
• The presence of a 10b5-1 plan (F1) means the sales were preplanned and executed automatically, reducing the likelihood that they reflect a discretionary decision about Jazz’s near-term prospects.
• For a complete picture (post-transaction holdings, exact per-trade fills), retail investors should review the full Form 4 and the issuer’s disclosures.